4.6 Article

Cognitive Profile of LRRK2-Related Parkinson's Disease

期刊

MOVEMENT DISORDERS
卷 30, 期 5, 页码 728-733

出版社

WILEY-BLACKWELL
DOI: 10.1002/mds.26161

关键词

cognition; LRRK2; neuropsychological tests; Parkinson's disease; working memory

资金

  1. National Institutes of Health [K23 NS060949, P50 NS062684, P50 NS053488, P50 NS038367, P50 NS038377, P50 NSO72187, R01 NS065070, R01 NS057567, U01 NS082133]
  2. U.S. Department of Veterans Affairs Merit Award [1I01BX000531]
  3. Parkinson's Disease Foundation
  4. Nancy and Buster Alvord Endowment
  5. Jane and Lee Seidman Fund
  6. Consolidated Anti-Aging Foundation

向作者/读者索取更多资源

BackgroundIncreasing evidence suggests that genetic factors play a role in the variability associated with cognitive performance in Parkinson's disease (PD). Mutations in the LRRK2 gene are the most common cause of monogenic PD; however, the cognitive profile of LRRK2-related PD is not well-characterized. MethodsA cohort of 1,447 PD patients enrolled in the PD Cognitive Genetics Consortium was screened for LRRK2 mutations and completed detailed cognitive testing. Associations between mutation carrier status and cognitive test scores were assessed using linear regression models. ResultsLRRK2 mutation carriers (n=29) demonstrated better performance on the Mini Mental State Examination (P=0.03) and the Letter-Number Sequencing Test (P=0.005). A smaller proportion of LRRK2 carriers were demented (P=0.03). ConclusionsOur cross-sectional study demonstrates better performance on certain cognitive tests, as well as lower rates of dementia in LRRK2-related PD. Future longitudinal studies are needed to determine whether LRRK2 mutation carriers exhibit slower cognitive decline. (c) 2015 International Parkinson and Movement Disorder Society

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Clinical Neurology

Teaching NeuroImages: The dentate sign in subacute cerebellar ataxia Metronidazole neurotoxicity

Merida Teran Jimenez, Philippe Salles Gandara, Alberto J. Espay

NEUROLOGY (2023)

Article Clinical Neurology

Prediction of neuropathologic lesions from clinical data

Thanaphong Phongpreecha, Brenna Cholerton, Syed Bhukari, Alan L. L. Chang, Davide De Francesco, Melan Thuraiappah, Dana Godrich, Amalia Perna, Martin G. Becker, Neal G. Ravindra, Camilo Espinosa, Yeasul Kim, Eloise Berson, Samson Mataraso, Sharon J. J. Sha, Edward J. Fox, Kathleen S. Montine, Laura D. Baker, Suzanne Craft, Lon White, Kathleen L. Poston, Gary Beecham, Nima Aghaeepour, Thomas J. Montine

Summary: This study used statistical tools and machine learning to predict 17 neuropathologic lesions based on 381 clinical features of 6518 individuals. The results showed high prediction performance for certain lesions. Some clinical features were strongly associated with multiple neurodegenerative diseases, while others were specific to certain lesions.

ALZHEIMERS & DEMENTIA (2023)

Article Clinical Neurology

Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology-Proven Cases

Luca Marsili, Kevin R. Duque, Nathan Gregor, Elhusseini Abdelghany, Jesus Abanto, Andrew P. Duker, Matthew C. Hagen, Alberto J. Espay, Matteo Bologna

Summary: This study found no significant differences in the features of bradykinesia between patients with synucleinopathies and tauopathies.

MOVEMENT DISORDERS (2023)

Article Clinical Neurology

Spectrum of Pediatric to Early Adulthood POLR3A-Associated Movement Disorders

Alonso Zea Vera, Adrienne Bruce, Travis R. Larsh, Zachary Jordan, Norbert Bruggemann, Ana Westenberger, Alberto J. Espay, Donald L. Gilbert, Steve W. Wu

Summary: POLR3A-related disorders exhibit significant phenotypic pleomorphism, including a range of movement disorders such as parkinsonism, dystonia, ataxia, and spasticity. Vertical gaze dysfunction and T2-weighted/FLAIR hyperintensity of the superior cerebellar peduncles and midbrain may be useful signs suggestive of this condition.

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

Article Clinical Neurology

Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated

John L. Robinson, Sharon X. Xie, Daniel R. Baer, EunRan Suh, Vivianna M. Van Deerlin, Nicholas J. Loh, David J. Irwin, Corey T. McMillan, David A. Wolk, Alice Chen-Plotkin, Daniel Weintraub, Theresa Schuck, Virginia M. Y. Lee, John Q. Trojanowski, Edward B. Lee

Summary: In this retrospective study, the incidence of 10 pathologies in neurodegenerative disease (ND) and normal aging was examined, with up to seven pathologies observed concurrently resulting in 161 different combinations. The presence of multiple additive pathologies was associated with factors such as longer disease duration, clinical dementia, older age, and APOE e4 status.
Article Clinical Neurology

Redefining Bradykinesia

Matteo Bologna, Alberto J. Espay, Alfonso Fasano, Giulia Paparella, Mark Hallett, Alfredo Berardelli

MOVEMENT DISORDERS (2023)

Editorial Material Clinical Neurology

Alpha-synuclein and the Parkinson's disease drug pipeline

Alberto J. Espay, Kevin McFarthing

Summary: The process of protein aggregation involves the transformation of soluble peptides into insoluble cross-beta amyloids. In Parkinson's disease, soluble monomeric a-synuclein transforms into the amyloid state known as Lewy pathology. Most disease-modifying projects in the therapeutic pipeline for Parkinson's disease aim to reduce the insoluble a-synuclein fraction, while none aim to increase soluble a-synuclein levels. We propose rebalancing the therapeutic pipeline to include treatments that restore soluble a-synuclein within a normal range.

PARKINSONISM & RELATED DISORDERS (2023)

Article Multidisciplinary Sciences

Brain proteomic analysis implicates actin filament processes and injury response in resilience to Alzheimer's disease

Zhi Huang, Gennifer E. Merrihew, Eric B. Larson, Jea Park, Deanna Plubell, Edward J. Fox, Kathleen S. Montine, Caitlin S. Latimer, C. Dirk Keene, James Y. Zou, Michael J. MacCoss, Thomas J. Montine

Summary: Resilience to Alzheimer's disease is a rare combination of high disease burden without dementia, which provides valuable insights into limiting clinical impact. Lowering soluble A beta concentration may suppress severe cognitive impairment along the Alzheimer's disease continuum.

NATURE COMMUNICATIONS (2023)

Article Clinical Neurology

Digital Biomarkers in Parkinson's Disease: Missing the Forest for the Trees?

Ashwani Jha, Alberto J. Espay, Andrew J. Lees

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

Article Clinical Neurology

Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia

Amalia Perna, Kathleen S. Montine, Lon R. White, Thomas J. Montine, Brenna A. Cholerton

Summary: Neurodegenerative dementia arises from various abnormalities and the co-occurrence of multiple processes complicates identifying effective treatment targets. Current treatments mainly focus on symptoms and recently approved drugs for disease structures only have moderate benefit on symptom progression. Ongoing trials explore cognition enhancers, new drug combinations, less toxic prodrugs, and drugs targeting neuroinflammation or microbiome. A paradigm shift towards individualized and multimodal treatments is necessary to advance dementia therapeutics effectively.

NEUROTHERAPEUTICS (2023)

Article Multidisciplinary Sciences

Whole genome deconvolution unveils Alzheimer's resilient epigenetic signature

Eloise Berson, Anjali Sreenivas, Thanaphong Phongpreecha, Amalia Perna, Fiorella C. Grandi, Lei Xue, Neal G. Ravindra, Neelufar Payrovnaziri, Samson Mataraso, Yeasul Kim, Camilo Espinosa, Alan L. Chang, Martin Becker, Kathleen S. Montine, Edward J. Fox, Howard Y. Chang, M. Ryan Corces, Nima Aghaeepour, Thomas J. Montine

Summary: The authors developed Cellformer, a deep learning method that deconvolutes bulk ATAC-seq into cell type-specific expression, allowing cost-effective cell type-specific open chromatin profiling. Applied to bulk samples from three brain regions, Cellformer identified cell type-specific gene regulatory mechanisms underlying resilience to Alzheimer's disease and suggested potential epigenetic mediators. The Cellformer tool is now freely available for future investigations using high-throughput bulk ATAC-seq data.

NATURE COMMUNICATIONS (2023)

Article Clinical Neurology

The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP)

Vindhya Koneru, Alberto J. Espay, Allan J. Cole, Daniel Weintraub, Kathleen Crist, Maria B. Pascual, William G. Ondo

MOVEMENT DISORDERS (2023)

暂无数据